NEWTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) — Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that company management will participate in the upcoming 12

^th

Annual Wedbush PacGrow Healthcare Conference on August 10

^th

– August 11

^th

, 2021.

Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in the

Casino Re-nal Part 2 – Cysts and Stones

panel discussion. Details for the panel discussion are below:

Management will also be available for 1×1 meetings on Tuesday, August 10

^th


– Wednesday, August 11

^th


, 2021.

About Allena Pharmaceuticals

Allena Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program planned for the second half of 2021.

Investor Contact


Ashley Robinson

LifeSci Advisors, LLC

617-430-7577


[email protected]

Media Contact


Adam Daley

Berry & Company Public Relations

212-253-8881


[email protected]